- Shadow Work: How Businesses Are Turning Us All Into Unpaid Laborers
- IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price
- Boomers' Biggest Retirement Regret? They Didn't Work Longer
- Carnival CEO Aims to Bust the Biggest Myths About the Cruise Industry
- The 10 Poorest States in America
Sarepta Therapeutics received the green light from U.S. regulators to finally file a new drug application for eteplirsen, the company's experimental therapy for Duchenne muscular dystrophy.
VWR Corporation will continue to grow through acquisitions and the strong dollar is not weighing down the lab equipment seller in Europe.
There's nothing wrong with being a biotech bull who can also raise legitimate questions and understand risks.
Allergan blazed a trail when its wrinkle-fighting treatment Botox opened up the facial aesthetics market. Now Kythera is attempting to follow that path with its double-chin drug Kybella.
Kythera has high expectations for the targeted launch of its FDA-approved double chin injection Kybella in the second half of 2015, said the company's CEO Keith Leonard.
Bluebird Bio and Intercept Pharma have reached separate agreements with regulators on the designs of key clinical trials for their respective blood disorder and fatty liver disease drugs.
The U.S. dominates the Biotech industry both in terms of number of firms with 6,862, and research and development spending with $26 billion in 2014.
Here are some of the best biotech companies TheStreet Quant Ratings says you should consider looking at.
The speculation of another hepatitis C-related acquisition took off Monday afternoon, sparked by a rumor that Gilead executives canceled a scheduled Tuesday presentation at a health care investor conference.
Tim Miller, CEO of PlasmaTech, says his company is focused on growing its pipeline and finding treatments for rare diseases.
Altera (ALTR) was the best performer on the S&P 500 Monday following reports the company has reopened negotiations with Intel (INTC).
PlasmaTech Biopharmaceuticals is enjoying a higher profile now that the business community is paying more attention to rare disease treatments, said the company's CEO Tim Miller.
Synergy Pharmaceuticals (SGYP) shares continue to gain after closing trading up double digits after hedge fund Paulson & Co. revealed a 2.1% stake in the company.
Horizon Pharmaceuticals (HZNP) stock performance is the subject of today's Trifecta Stocks 'Chart of the Day' analysis.
Mongersen is one of Celgene's most important pipeline drugs and a potential blockbuster treatment for Crohn's disease, an auto-immune disorder affecting the bowel.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV